Page 198 - Mercy MOR All Regions_FinalwVideo
P. 198
Key Performance Indicators Metric Willard Hospital Variance ($120) % Variance 19.3% Prior 11.9%
Actual
Budget
$268,790
$309,453
$249,424
($60,029)
-24.1%
Supply Expense
4.0%
$2,267,533
$2,376,993
$91,952
Net Patient Revenue
$2,285,041
13.0%
2.1%
Supply Expense % Net Patient Revenue
10.9%
$1,068
-12.7%
$948
$980
Supply Expense per EIPA
Total Admissions
58
49
24.5%
61
12
237
184
28.8%
Total Patient Days
214
53
10.3%
274
Total EIPAs
290
27
263
8
5
2
40.0%
IP Surgeries
7
OP Surgeries
80
68
-11.8%
85
(10)
Total Surgeries
75
71
Site Performance Summary (12) -15.0% 63
Willard's supply expense was unfavorable to budget by 24.1% ($60K), mostly driven by excess drug spend ($53.6K) on high-
dollar IV infusions. Additional areas of unfavorable spend included Implant - Ortho, Implant - Other, both driven by an
increase in Inpatient volume (40% over budget). Unfavorable spend is also found in Med/Surg, and Lab, driven by increases
in Admissions (24.5% to budget) and Total Patient Days (28.8% to budget) correspondingly contributed to these areas.
Further, overall flu supply spend was $5.3K over prior year, specifically notable in Lab & IV/IV Sets subaccounts.
Willard Hospital Leader's Summary
Key Challenges
High Admissions and Patient Days compared to both PY and Budget with influx of flu patients.
Also had a few infrequent Med/Surg supply purchases of $1K+/EA from the OR. Spend was
unfavorable to budget by 15% for these reasons.
Med/Surg
Driven heavily by patient treatments requiring high-dollar drugs such as Keytruda and Krystexxa
contributed $50K toward drug spend.
Rx
Ortho volumes increased over prior year, putting subaccount over by $5.5K; however, cost per
case decreased an average of over $.8K/case.
Implants
Lab: Supply spend unfavorable to budget by 24%, driven in-part by flu supplies as well as
expanded testing.
Instruments: ($4.9K over budget); Additional instruments needed to support increased inpatient
Other Expenses
volumes.
Actions Taken/Planned:
Working to identify and review Pharmacy initiatives for 2018 that could be favorable to Drug
Rx
supply spend.
Working with Surgery/OR Leadership on Instrument and Minor Equipment spend to identify
Surgery/OR
areas of need in '18.
